Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLEXERIL vs ESTROSTEP 21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
Prevention of pregnancy,Treatment of moderate acne vulgaris in females >= 15 years of age who have achieved menarche, are not pregnant, and desire oral contraception
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours (terminal). Steady-state achieved within 3-5 days.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Ethinyl estradiol is metabolized primarily via CYP3A4 and undergoes glucuronidation and sulfation. Norethindrone acetate is deacetylated to norethindrone, which is metabolized by CYP3A4 and other CYP enzymes, and undergoes reduction and glucuronidation.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Biliary/fecal (40-50% as metabolites) and renal (30-40% as glucuronide and sulfate conjugates)
~93% bound to plasma proteins, primarily albumin.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 95-97% bound to albumin and SHBG.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
Ethinyl estradiol: 2.5-4.5 L/kg; norethindrone: 3.5-5.5 L/kg. Indicates extensive tissue distribution.
Oral: ~33% due to extensive first-pass metabolism.
Ethinyl estradiol: 38-48% (oral, first-pass metabolism); norethindrone acetate: 50-70% (oral, deacetylation to norethindrone).
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Contraindicated in acute hepatitis, severe cirrhosis, benign or malignant liver tumors, or Child-Pugh class C cirrhosis. Use with caution in Child-Pugh class A or B; consider alternative therapy.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Not indicated for use before menarche. Post-menarche: same dosing as adults; use lowest effective dose for shortest duration.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
Not indicated for postmenopausal women; no established dosing in elderly. Consider alternative therapies as necessary.
None
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women > 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction), especially in smokers and women over 35,Hepatic neoplasia (benign and malignant) reported,Hypertension and gallbladder disease,Carbohydrate and lipid effects; monitor in diabetic patients,Ocular lesions (e.g., retinal thrombosis); discontinue if unexplained vision loss or proptosis occurs,Hereditary angioedema exacerbation,Chloasma; avoid sun exposure,Menstrual irregularities (e.g., breakthrough bleeding, amenorrhea),Depression; discontinue if severe
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
Thrombophlebitis, thromboembolic disorders, or history thereof (e.g., deep vein thrombosis, pulmonary embolism),Cerebrovascular disease (e.g., stroke, TIA),Coronary artery disease (e.g., myocardial infarction, angina),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Benign or malignant liver tumors,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35 years of age
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
No specific food interactions. Grapefruit juice may increase estrogen exposure (mild effect). Maintain consistent timing with meals to reduce nausea if needed. Avoid alcohol if liver function is compromised.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and neural tube defects. Second and third trimesters: associated with fetal genital abnormalities, feminization of male fetuses, and potential long-term reproductive effects. Use in early pregnancy for emergency contraception is not recommended due to potential risks.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
Estrostep 21 is excreted in breast milk in small amounts; ethinyl estradiol M/P ratio approximately 0.1; norethindrone M/P ratio ~0.5. May reduce milk production and quality, especially in early lactation. Use generally avoided during breastfeeding; consider progestin-only alternatives.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Estrostep 21 is contraindicated in pregnancy; no dose adjustments recommended as use is avoided. Pharmacokinetic changes during pregnancy (increased hepatic metabolism, volume of distribution) would require dose adjustment if used, but due to risks, alternative therapy is indicated.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
ESTROSTEP 21 is a monophasic oral contraceptive containing norethindrone acetate and ethinyl estradiol. Due to its low estrogen dose (20 mcg), it may be associated with more breakthrough bleeding compared to higher-dose pills. It is indicated for contraception and may be used for acne treatment. The 21-day regimen requires a 7-day hormone-free interval. Counsel patients that smoking increases the risk of serious cardiovascular adverse effects; avoid in women over 35 who smoke.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
Take one tablet daily at the same time each day for 21 days, then no pills for 7 days.,If you miss a dose, follow the package instructions; use backup contraception if missed more than one tablet.,Do not smoke while taking this medication; smoking increases risk of blood clots, stroke, and heart attack, especially if over 35.,Common side effects include spotting, nausea, breast tenderness, and headache; these often improve after a few cycles.,Seek emergency care if you have signs of a blood clot: sudden leg pain, chest pain, shortness of breath, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Take missed pills as soon as remembered; do not take more than two tablets in one day.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLEXERIL vs ESTROSTEP 21, answered by our medical review team.
FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. ESTROSTEP 21 is a Combined Oral Contraceptive that works by Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLEXERIL and ESTROSTEP 21 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. The standard adult dose of ESTROSTEP 21 is: One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLEXERIL and ESTROSTEP 21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . ESTROSTEP 21 is classified as Category C. Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.